InsiderPulse
Dashboard

CRSP

CRISPR Therapeutics AG

Health CareRussell 2000

CRISPR Therapeutics AG insider trading

CRISPR Therapeutics AG files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in Zug. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent CRSP insider transactions

5 insiders traded CRSP on the open market between Feb 19, 2026 and Sep 17, 2026 — 14 sales worth $4.2M.

Bought
—
Sold
$4.2M

none on a 10b5-1 plan

Net
−$4.2M
Insiders
5

Open-market purchases (code P) and sales (code S) from CRISPR Therapeutics AG's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 22, 2026. The live dashboard shows new filings the moment they clear.

Every CRSP Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

CRSP insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 8 insiders traded CRSP on the open market: 6 purchases worth $53M and 50 sales worth $24.9M, 16 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 4 purchases ($52.6M) and 27 sales ($17.6M), by 6 insiders.

QuarterBoughtSold
Q2 2026—−$210.6K1 sale
Q1 2026—−$12.3M19 sales · 7 on a plan
Q4 2025—−$4.4M6 sales · 3 on a plan
Q3 2025+$52.6M4 buys−$760.7K1 sale
Q2 2025+$49.7K1 buy−$141.3K1 sale
Q1 2025+$314K1 buy−$4.4M17 sales · 3 on a plan
Q4 2024—−$2.7M5 sales · 3 on a plan
Q3 2024——
Largest purchase
+$50M of CRSP by George Simeon (Director) on Jul 16, 2025.
Largest sale
−$3.6M of CRSP by Kulkarni Samarth (Chief Executive Officer · Director) on Jan 22, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Kulkarni Samarth10b5-1

    Chief Executive Officer · Director

    −$3.6M

    Jan 22, 2026

    60,000 sh · $60.23

  • Prasad Raju10b5-1

    Chief Financial Officer

    −$2.1M

    Jan 22, 2026

    34,972 sh · $60.19

  • Kulkarni Samarth10b5-1

    Chief Executive Officer · Director

    −$1.1M

    Jan 20, 2026

    21,433 sh · $51.61

  • Kulkarni Samarth10b5-1

    Chief Executive Officer · Director

    −$446.3K

    Jan 20, 2026

    8,567 sh · $52.10

  • Prasad Raju10b5-1

    Chief Financial Officer

    −$1.1M

    Jan 06, 2026

    18,933 sh · $60.18

  • Prasad Raju10b5-1

    Chief Financial Officer

    −$347K

    Jan 06, 2026

    5,763 sh · $60.21

  • Prasad Raju10b5-1

    Chief Financial Officer

    −$300.2K

    Jan 06, 2026

    5,004 sh · $60.00

  • Prasad Raju10b5-1

    Chief Financial Officer

    −$308.2K

    Dec 22, 2025

    5,472 sh · $56.33

  • Prasad Raju10b5-1

    Chief Financial Officer

    −$194.4K

    Dec 22, 2025

    3,528 sh · $55.10

  • Prasad Raju10b5-1

    Chief Financial Officer

    −$56.9K

    Dec 22, 2025

    1,000 sh · $56.89

  • Kulkarni Samarth

    Chief Executive Officer · Director

    −$3.5M

    Oct 17, 2025

    50,895 sh · $67.91

  • Kulkarni Samarth

    Chief Executive Officer · Director

    −$282.5K

    Oct 14, 2025

    4,242 sh · $66.60

  • Kasinger James R.

    General Counsel and Secretary

    −$71.7K

    Oct 14, 2025

    1,076 sh · $66.60

  • Kulkarni Samarth

    Chief Executive Officer · Director

    −$760.7K

    Aug 18, 2025

    13,081 sh · $58.15

  • Treco Douglas A

    Director

    +$1.1M

    Aug 06, 2025

    20,000 sh · $57.03

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

CRISPR Therapeutics AG company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
Zug
Incorporated in
V8
Listed on
Nasdaq
SEC Central Index Key
0001674416

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought CRSP

What the stock actually did in the 90 days following each open-market purchase

Don't check CRSP — let it ping you

Get told the moment an insider moves on CRSP

Pro watches CRISPR Therapeutics AG for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add CRSP to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track CRSP on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read CRSP insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

NTLABEAMRXRXTWSTPACBARWRIONSAXSMKRYSRAREFOLDACAD
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are CRSP insiders buying or selling?
Between Feb 19, 2026 and Sep 17, 2026, 5 CRISPR Therapeutics AG insiders made no open-market purchases and 14 sales worth $4.2M, a net sale of $4.2M.
How much CRSP stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 8 CRISPR Therapeutics AG insiders made 6 open-market purchases worth $53M and 50 sales worth $24.9M. 16 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 4 purchases ($52.6M) and 27 sales ($17.6M). The largest purchase was George Simeon buying $50M on Jul 16, 2025. The largest sale was Kulkarni Samarth selling $3.6M on Jan 22, 2026.
What was the largest recent CRSP insider trade?
Behbahani Ali (Director) sold $780.9K of CRSP stock on Sep 17, 2026 at about $57.09 a share.
When did an insider last buy CRSP shares?
No open-market purchase by a CRISPR Therapeutics AG insider appears in the filings from Feb 19, 2026 to Sep 17, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Treco Douglas A buying $1.1M on Aug 06, 2025.
Where does CRSP insider trading data come from?
From the Form 4 filings CRISPR Therapeutics AG's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.